Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Collegium Pharmaceutical Inc (COLL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/27/2025: COLL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 20.04% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 02/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 959.13M USD | Price to earnings Ratio 16.05 | 1Y Target Price 42.8 |
Price to earnings Ratio 16.05 | 1Y Target Price 42.8 | ||
Volume (30-day avg) 338077 | Beta 0.99 | 52 Weeks Range 27.27 - 42.29 | Updated Date 04/1/2025 |
52 Weeks Range 27.27 - 42.29 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.86 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.96% | Operating Margin (TTM) 23.97% |
Management Effectiveness
Return on Assets (TTM) 8.89% | Return on Equity (TTM) 32.62% |
Valuation
Trailing PE 16.05 | Forward PE 4.36 | Enterprise Value 1655669170 | Price to Sales(TTM) 1.52 |
Enterprise Value 1655669170 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 2.62 | Enterprise Value to EBITDA 4.85 | Shares Outstanding 32131800 | Shares Floating 27037878 |
Shares Outstanding 32131800 | Shares Floating 27037878 | ||
Percent Insiders 2.29 | Percent Institutions 121 |
Analyst Ratings
Rating 4.2 | Target Price 43 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Collegium Pharmaceutical Inc
Company Overview
History and Background
Collegium Pharmaceutical, Inc. was founded in 2003. It focused on developing and commercializing abuse-deterrent opioid medications. Over time, it has grown through organic development and acquisitions.
Core Business Areas
- Pain Management: Develops and commercializes products for the treatment of pain, focusing on abuse-deterrent formulations.
Leadership and Structure
The company has a management team led by a CEO, CFO, and CMO. The structure includes departments for R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Xtampza ER: An extended-release oxycodone formulation designed with abuse-deterrent properties. Market share varies; exact figures not publicly available. Competitors include Purdue Pharma (OxyContin), Teva Pharmaceutical (generic oxycodone), and other pain medication manufacturers.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically pain management, is competitive and heavily regulated. There's increasing pressure to develop non-opioid alternatives and abuse-deterrent opioid formulations.
Positioning
Collegium Pharmaceutical is positioned as a company specializing in abuse-deterrent opioid medications. Their competitive advantage lies in their formulation technology.
Total Addressable Market (TAM)
The total addressable market for pain management is significant. Collegium's positioning focuses on a niche within this market.
Upturn SWOT Analysis
Strengths
- Abuse-deterrent technology
- Specialized focus on pain management
- Established commercial infrastructure
Weaknesses
- Dependence on opioid market
- Regulatory scrutiny
- Single product concentration
Opportunities
- Expansion into non-opioid pain medications
- Partnerships with other pharmaceutical companies
- International market expansion
Threats
- Generic competition
- Changes in prescribing guidelines
- Litigation risks associated with opioid products
Competitors and Market Share
Key Competitors
- TEVA
- PDLI
Competitive Landscape
Collegium competes with larger pharmaceutical companies. Their advantage is abuse-deterrent technology, but they lack the resources of larger competitors.
Major Acquisitions
BioDelivery Sciences International (BDSI)
- Year: 2022
- Acquisition Price (USD millions): 604
- Strategic Rationale: To expand its pain management portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends cannot be assessed without financial data.
Future Projections: Future projections cannot be provided without analyst estimates.
Recent Initiatives: Recent initiatives might include new product development or strategic partnerships.
Summary
Collegium Pharmaceutical is a specialized pharmaceutical company focused on pain management with abuse-deterrent technology. Its acquisition of BioDelivery Sciences International expanded its portfolio. The company faces challenges related to opioid regulation and competition. Continued innovation and strategic partnerships are vital for sustained growth.
Similar Companies
- TEVA
- PDLI
- ENDP
Sources and Disclaimers
Data Sources:
- Publicly available information, company press releases, industry reports.
Disclaimers:
This analysis is based on limited information and simulated data. Actual financial data and market conditions may differ.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collegium Pharmaceutical Inc
Exchange NASDAQ | Headquaters Stoughton, MA, United States | ||
IPO Launch date 2015-05-07 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 357 | Website https://www.collegiumpharma.com |
Full time employees 357 | Website https://www.collegiumpharma.com | ||
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.